Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (HOLA)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Multiple Myeloma; Non-Hodgkin; Lymphoma; Leukemia; Lymphoid

Treatments: Other: Chronic Lymphocytic Leukemia (CLL); Other: Multiple Myeloma (MM); Other: Non-Hodgkin's lymphoma (NHL)

Study type: Observational

Funder types: Industry

Identifiers

NCT02559583

CR105066

PCI-32765MMY4001 (Other Identifier)

Details and patient eligibility

About

The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America.

Full description

This is a retrospective (take a look back at events that already have taken place), non-interventional, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adult participants with a diagnosis of CLL, MM or NHL anytime since 01 January 2006. Only data available from clinical practice will be collected. All eligible participants at participating centers will be included regardless of participant's demographics, prior or current treatments for disease, or clinical outcome. The period of observation will span from 01 January 2006 through present, but all eligible participants must be followed for a minimum of 1 year, unless the participant died within that first year. Participant demographic parameters, standard therapies, treatment patterns and outcomes will be primarily quantified.

Enrollment: 5,443 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) anytime since January 1, 2006
• At least one year of data following first observed diagnosis except in the case of the participant death within one year following first observed diagnosis
• Participant must sign a participation agreement/informed consent form (ICF)

Exclusion criteria

• Having one and only one consult in the center

Trial design

5,443 participants in 3 patient groups

Participants with Chronic Lymphocytic Leukemia (CLL)

Description:

This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.

Treatment:

Other: Chronic Lymphocytic Leukemia (CLL)

Participants with Multiple Myeloma (MM)

Description:

This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.

Treatment:

Other: Multiple Myeloma (MM)

Participants with Non-Hodgkin's lymphoma (NHL)

Description:

This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.

Treatment:

Other: Non-Hodgkin's lymphoma (NHL)